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Abstract
Background: BCL-xL is an anti-apoptotic BCL-2 family protein that inhibits apoptosis and is overexpressed in many
cancers. We have reported that acquired resistance to the BCL-2 inhibitor ABT-199 (venetoclax) is associated with
increased BCL-xL expression. Yet, how BCL-xL mediates chemoresistance in hematopoietic malignancies is not clear.
This finding may help in design of new strategies for therapeutic intervention to overcome acquired chemoresistance
mediated by BCL-xL.
Results: We now show that the increased BCL-xL expression was inversely correlated with that of miR-377 in
ABT-199-resistant cells. This finding was also extended to a panel of B-cell lymphoid lines and primary chronic
lymphocytic leukemia (CLL) cells. miR-377 suppressed BCL-xL expression by recognizing two binding sites in
the BCL-xL 3’-UTR. Mutation of these two miR-377 consensus-binding sites completely abolished its regulatory
effect. Expression of a miR-377 mimic downregulated BCL-xL protein expression and significantly increased
apoptotic cell death. Expression of a miR-377 inhibitor restored BCL-xL protein expression and limited cell
death caused by the hypomethylating agent 5-azacytidine. Thus, miR-377-dependent BCL-xL regulation drives
acquired therapeutic resistance to ABT-199. We further show that CLL patients who received a diverse array
of chemotherapy regimens also had significantly higher BCL-xL and lower miR377 expression, indicating that
exposure to chemotherapy might trigger transcriptional silencing of miR-377, which results in high levels of
BCL-xL. Importantly, CLL patients with high BCL-xL/low miR-377 expression had an advanced tumor stage.
Moreover, the high BCL-xL expression correlated with short treatment-free survival in 76 CLL patients. miR-377 is located
at 14q32 in the DLK1-DIO3 region, which encodes the largest tumor suppressor miRNA cluster in humans. Examination
of five additional 14q32 miRNAs revealed that the majority were significantly down-regulated in most CLL patients as
well as in ABT-199-resistant cell lines. Remarkably, four of these miRNAs had significantly decreased expression in
chemotherapy-treated CLL patients as compared to those untreated. These findings indicate a reduced expression of
multiple miRNAs that may reflect a global silencing of this miRNA cluster in therapy-resistant lymphoid cells.
Conclusions: These findings reveal a novel mechanism by which down-regulation of miR-377 increases BCL-xL
expression, promoting chemotherapy resistance in B-cell lymphoid malignancies.
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Background
The BCL-2 family proteins regulate apoptosis primarily
on the mitochondrial outer membrane through the
intrinsic apoptotic pathway [1, 2]. These proteins are
divided into three classes based on their BCL-2 homology
(BH) domains (BH1-BH4) and function [3]: anti-apoptotic
[BCL-2, BCL-xL, BCL-W, MCL-1, BCL2A1 (BFL-1, A1),
and BCL-B], pro-apoptotic multi-domain effectors (BAX
and BAK), and BH3-only proteins (e.g. BIM, PUMA, and
NOXA). Inhibition of apoptosis is accomplished by se-
questering pro-apoptotic proteins and thus preventing
mitochondrial outer membrane permeabilization [4].
Blocked apoptosis is a hallmark of treatment-resistant
cancers and thus it suggests that BCL-2 family members
have potential as clinical biomarkers [1, 5]. In fact, sev-
eral studies have linked BCL-2 family expression and re-
sponse to chemotherapy in different types of cancers. It
has been reported that patients with cancers highly
“primed” to cross the apoptotic threshold exhibit super-
ior clinical responses to chemotherapy [6]. For chronic
lymphocytic leukemia (CLL), high BCL-2 and MCL-1
expression levels have been reported to mediate resist-
ance to chlorambucil, fludarabine, and rituximab [7–9].
Although numerous studies have focused on the role of
BCL-2 or MCL-1 in CLL, the role of other anti-
apoptotic proteins and their contribution to clinical
outcome is not clearly defined. Most importantly,
pharmacologic inhibitors of BCL-2 family proteins are
poised for widespread clinical use, so there is an imme-
diate need for development of markers that can ration-
ally direct and better personalize the use of these agents
in the clinic [10]. We have developed an anti-apoptotic
BCL-2 family expression index that can predict the re-
sponse of hematological cells, including CLL, as well as
solid tumor malignancies, to the rationally designed
BCL-2 family inhibitor, ABT-737/ABT-263 (navitoclax)
[11]. ABT-199 (venetoclax), a second-generation, ra-
tionally designed inhibitor that was re-engineered to
bind selectively to BCL-2, shows anti-tumor activity in
primary tumor cells and xenograft models [12, 13].
Phase I clinical trials with ABT-199 have had high
patient response rates that include many complete
responses [14].
Lymphoid malignancies, most commonly derived from
B-cell precursors include more than 40 distinct tumor
types, varying widely in phenotype and clinical behavior
[15]. CLL, the most common leukemia in the Western
world [16], is characterized by an expansion of small ma-
ture B cells in blood, lymph nodes, and bone marrow. Its
heterogeneous clinical course [17, 18] has led to a search
for markers that can predict disease progression to allow
better management of the disease. Mutational status of
the immunoglobulin heavy chain variable (IGHV) region
dichotomizes CLL patients into two risk categories: those
with unmutated IGHV have an unfavorable prognosis,
whereas patients with mutated IGHV tend to have a more
favorable prognosis. ZAP70 and CD38 expression can
serve as a surrogate for an unmutated IGHV gene, thus
functioning as prognostic markers [19, 20]. Despite of
their clinical value, there are technical difficulties that
preclude optimal use of these markers, such as
standardization and reproducibility [21, 22]. In addition,
p53 deletion is a well-established marker of shorter
survival and chemotherapy resistance [23]; however, it is
present in only a small percentage of patients with CLL at
the initial diagnosis [24, 25]. Overall, existing established
prognostic markers fail to predict clinical outcome in a
considerable number of patients with CLL [24]. Moreover,
it is difficult to integrate the results of these various
markers to assess the overall risk in an individual patient
[22]. Thus, developing additional markers for CLL is of
considerable interest as they may indicate inherent
biologic differences that may be amenable to targeted
therapeutic intervention.
MicroRNAs (miRs) are small non-coding regulatory
RNAs that bind to a specific target mRNA through a se-
quence that is complementary primarily to the 3’-UTR
of the target mRNA. They have roles in many underlying
cancer processes, including proliferation, apoptosis, and
invasion [26, 27]. miRNAs are very stable and are found
in body fluids such as plasma, serum, and urine, there-
fore cancer-specific miRNAs could potentially be used
as a tumor molecular signature to track and predict can-
cer progression and to guide treatment [28].
Here, we report that high BCL-xL expression inversely
correlated with decreased levels of a newly identified
miR-377. Mutational and functional analyses validated
BCL-xL as a direct target of miR-377. Moreover, we
show that BCL-xL/miR-377 regulation in diffuse large B-
cell lymphoma (DLBCL) cells drives acquired thera-
peutic resistance to ABT-199 and is associated with
advanced tumor stage in CLL patients. Collectively,
these data support a model in which co-regulation of
BCL-xL and miR-377 mediates a novel mechanism of
acquired therapeutic resistance in B-cell lymphoid
malignancies.
Results
High BCL-xL expression mediates chemotherapy
resistance to ABT-199 in B-cell lymphoid malignancies
ABT-199 is a rationally designed selective BCL-2 inhibi-
tor that has shown promising results in clinical trials, so
understanding the mechanism of acquired resistance to
it is important. To this end, we generated ABT-199-
resistant (ABT-199R) cell lines from initially sensitive
SU-DHL-6 and OCl-LY19 DLBCL cells derived from
germinal center B cells (GCB). These GCB-DLBCL cell
lines with initial low expression of BCL-xL are ideally
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suited for studying the correlation of high BCL-xL and
acquired resistance to chemotherapy [29]. Using a
chronic exposure protocol we have described previously
[30], we show that SU-DHL-6-199R (S6-R) and OCL-
LY-19-199R (OC-R) cells were 4-and 3-fold more resist-
ant, respectively to ABT-199 [31] than parental cells.
BCL-xL mRNA levels, as determined by RT-PCR, were
more than three-fold higher in ABT-199R OC-R and S6-
R as compared to the parental OC and S6 cells (Fig. 1a).
As we have previously shown that acquired resistance to
ABT-737 occurs via elevated MCL-1 levels that seques-
ter the pro-apoptotic protein BIM [30], leading to a
block of apoptosis in response to ABT-737, we examined
whether BCL-xL directly mediates ABT-199 resistance
by sequestering BIM. Immunoprecipitation of BCL-xL
and examination of BIM levels revealed that more BCL-
xL-interactive BIM was present in the S6-R cells as com-
pared with the parental cells [31], indicating its
functional importance in regulating apoptosis resistance.
BCL-xL is regulated at the post-transcriptional level by
miR-377
To address the molecular mechanism that mediates high
BCL-xL RNA levels in resistant cells, we first
determined whether BCL-xL is regulated at the tran-
scriptional level by examining activation of the known
BCL-xL regulatory transcription factors, STAT3 and NF-
κB [32]. As these transcription factors were not activated
in our ABT-199R cells (data not shown), it is less likely
that the high BCL-xL expression observed is a result of
transcriptional regulation.
We next addressed the possibility that altered BCL-xL
RNA stability is controlled by a miRNA. Using target
prediction software (microRNA.org) to identify miRNAs
that have a putative BCL-xL target, we found that miR-
377 had the highest score rank of all candidates (Table 1).
We decided to focus on miR-377 for two reasons: (i) the
prediction analysis identified two complementary se-
quences in the 3’-UTR of BCL-xL mRNA that miR-377
is likely to base-pair with (Additional file 1: Figure S1A),
thus suggesting that it is a potential target, and (ii) miR-
377 is located at 14q32, the deleted chromosome 14 re-
gion that has been described in B-cell lymphomas [33],
suggesting that miR-377 may function as a tumor sup-
presser gene. To test whether miR-377 mediates BCL-xL
expression, we first examined whether its expression was
associated with that of miR-377. Indeed, expression of
miR-377 inversely correlated with that of BCL-xL in
ABT-199R cells (Fig. 1b).
BCL-xL is a direct target of miR-377
Bioinformatics analysis of the BCL-xL 3’-UTR using
RNAhybrid and miRbase predicted two potential binding
sites for miR-377 at positions 1238 and 1412 (Additional
file 1: Figure S1A). To examine whether BCL-xL is a dir-
ect target of miR-377, we monitored its expression using
a 3’-UTR luciferase reporter assay to examine whether
the observed reduction in BCL-xL expression during
miR-377 up-regulation is a result of a direct targeting of
its 3’-UTR by miR-377. We thus cloned a region of
BCL-xL 3’-UTR (1107 to 1491 nucleotides) containing
both of the predicted binding sites downstream of the
stop codon of the firefly luciferase open reading frame
(Fig. 1c). We also generated mutants (MUT) of miR-377
target sites (Fig. 1d). In the C1 and C2 3’-UTR mutants,
seven nucleotides 1238–1244 and 1412–1418, respect-
ively of the target site were mutated to disrupt miR-377
interaction in the predicted seed region (Fig. 1e). In the
third C3 mutant (double 3’-UTR mutant), we combined
both upstream and downstream miR-377 seed region
mutations in order to simultaneously disrupt the miR-
377/BCLxL interaction at both sites (Fig. 1e). Each of
these constructs was co-transfected with either a miR-
377 or a negative control mimic in CHO-K1 cells, with
renilla luciferase used as an internal control, and the lu-
ciferase activity was measured after 48 h. Ectopic miR-
377 mimic expression down-regulated the wild-type
(WT) 3’-UTR-associated luciferase activity by ~ 46 % as
compared with the negative control mimic (Fig. 1f ).
Cells transfected with C1- and C2 3’-UTR luciferase re-
porter and the miR-377 mimic showed reversal of this
repression in reporter activity by 22 and 36 %, respect-
ively (Fig. 1f ). Remarkably, in cells transfected with the
C3 double mutant 3’-UTR luciferase reporter, miR-377
mimic expression was unable to suppress luciferase ac-
tivity at all. These cells exhibited a complete reversal of
luciferase activity, which indicates a direct binding of
miR-377 to the predicted target sites in the BCL-xL 3’-
UTR (Fig. 1f ). Taken together, these data demonstrate
that the predicted target sites in the BCL-xL 3’-UTR are
authentic and specific binding sites for miR-377 and,
therefore, provide support to our discovery of BCL-xL as
a direct target of miR-377.
Using both mFold and Nupack RNA folding algo-
rithms, we analyzed the contextual/local secondary
structures around the predicted miRNA target site in
the short and full length 3’-UTR of BCL-xL transcript to
eliminate the possibility that different secondary struc-
tures may influence miRNA binding. Thus, the context-
ual structure between the secondary structure of the
short and the full-length BCL-xL 3’-UTRs, as predicted
by mFold RNA folding algorithm, appears to be very
similar as both contain six varied size bulges and an
almost similar number of helices (Additional file 1:
Figure S1B). Therefore, irrespective of the size of the
3’-UTR fragment utilized for target validation assay, our
analyses support our above findings that BCL-xL is a
target of miR-377. As a second independent approach
Al-harbi et al. Molecular Cancer  (2015) 14:185 Page 3 of 17
Fig. 1 (See legend on next page.)
Al-harbi et al. Molecular Cancer  (2015) 14:185 Page 4 of 17
to experimentally confirm that miR-377 is involved in the
regulation of BCL-xL, a gain-of-function experiment indi-
cated that adding miR-377 mimics at a concentration as
low as 50 nM led to a substantial decrease in endogenous
BCL-xL protein expression, thus confirming that miR-377
is a direct target of BCL-xL (Fig. 1g).
miR-377-dependent BCL-xL regulation drives resistance to
ABT-199
To address the molecular mechanism that mediates
down regulation of miR-377 in ABT-199- resistant cell
lines, we hypothesized that miR-377 might be epigeneti-
cally silenced, as several studies reported that miRs are
regulated by methylation [34–36]. Indeed, treatment of
ABT-199R cells with the DNA-hypomethylating agent
5-Aza-2′-deoxycytidine (5-Aza) for 72 h led to re-
expression of miR-377, which was also associated with a
decrease in BCL-xL expression (Fig. 2a and b), indicating
a tight regulation at the molecular level between BCL-xL
and miR-377 expression. Interestingly, ABT-199R cells
were highly sensitive to 5-Aza as compared to parental
cells (Fig. 2c), indicating that targeting BCL-xL by re-
expression of miR-377 can significantly increase cell death
(P < 0.005) of ABT-199R cells. Moreover, targeting BCL-
xL in S6-R cells by transfecting either miR-377 mimics or
siBCL-xL led to decrease in BCL-xL expression and sig-
nificant increase (P < 0.005) in cell death (Fig. 2d and e).
Importantly, expression of BCL-xL significantly increased
cell viability (P = 0.017) in miR-377 mimic-treated S6-R
cells (Fig. 2f and g). These results indicate that BCL-xL
expression can rescue cell viability after treatment with
the miR-377 mimic.
To demonstrate that re-expression of miR-377 by 5-
Aza impacts on BCL-xL expression, we sought to inhibit
miR-377 function with a miR-377 inhibitor consisting in
a single-strand reverse complement to the mature miR-
377 strand, which is used for preventing its binding to
endogenous targets. We therefore treated S6-R cells with
5-Aza for 24 h and then transfected them with the miR-
377 inhibitor and then assessed cell viability and BCL-xL
expression after 48 h (72 h total time of treatment). Our
data indicate that targeting miR-377 led to a substantial
blunting of the effect of 5-Aza, as indicated by a signifi-
cant decrease in cell death (P = 0.04) and BCL-xL
expression (Fig. 2h and i).
High BCL-xL expression correlates with low miR-377
expression in B-cell lymphoid malignancies, including CLL
patients
We next addressed the generality of the association of
BCL-xL and miR-377 expression in a panel of lymph-
oid B-cell lines. Remarkably, high BCL-xL expression
inversely correlated with low miR-377 expression in
the seven cell lines examined (Fig. 3a). Importantly,
expression of miR-377 inversely correlated (P < 0.001,
r = −0.82) with that of BCL-xL in primary CLL patient
samples (Fig. 3b and c). Interestingly, we also found
that cell lines that have high BCL-xL and low miR-
377 expressions are highly resistant to ABT-199
(Additional file 2: Figure S2). In addition, two out of
the three cell lines that have high BCL-xL and low
miR-377 expression were established from relapsed/
higher tumor stage patients.
Next, we wanted to test whether expression of BCL-xL
and miR-377 correlate with the severity of the clinical
course in CLL patients. Indeed, CLL patients with high
BCL-xL/low miR-377 have more advanced tumor stage
than CLL patients with low BCL-xL/high miR-377 ex-
pression (Fig. 3d). Importantly, CLL patients that were
previously treated with a wide range of chemotherapeu-
tic regimens had decreased miR-377 expression as com-
pared to untreated CLL patients (Fig. 3e), indicating that
exposure to chemotherapy might trigger transcriptional
silencing of miR-377, which results in high levels of
BCL-xL. These finding may reveal a new mechanism of
resistance, in which transcriptional silencing of miR-377,
which results in high levels of BCL-xL promotes resist-
ance to chemotherapy.








(See figure on previous page.)
Fig. 1 BCL-xL is a direct target of miR-377. a BCL-XL expression, as determined by quantitative RT-PCR in ABT-199-resistant (ABT-199R) OC-R and
S-6R relative to those in parental OCI-LY19 (OC) and SU-DHL-6 (S6) and cell lines. b RT-PCR analysis of BCL-xL and miR-377 expression levels in:
parental OC, S6, and ABT-199R derivative OC-R and S6-R cells. c Schematic representation of firefly luciferase reporter constructs containing the
384-nucleotide sequence from the BCL-xL 3’-UTR and the corresponding binding regions for miR-377. d miR-377 target sequence base pairing in
BCL-xL 3’-UTR. e Schematic of the mutant constructs. f Luciferase reporter activity in CHO-K1 cells co-transfected with BCL-xL WT-3’-UTR or
MUT-3’-UTR constructs: mutants C1, C2, and C3 (double-mutant) and miR-377 or negative control (NC) mimics (10 nM) as indicated. g BCL-xL
levels were assessed by immunoblot in 293 T cells transfected with miR-377 mimic at two concentrations (50 and 100 nM). β-actin was used as a
loading control
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miRNAs in the 14q32 cluster region are down-regulated
in therapy-resistant cells
It has been previously shown that miR-377 is located at
14q32.31. This region on the long arm of chromosome
14 encodes one of the largest miRNA clusters in humans
and is classified into two adjacent miRNA clus-
ters:14q32.31 and 14q32.32 [37]. Therefore, we wanted
to test whether the reduced expression of miR-377 is
unique or reflects a broader silencing of the mIRs lo-
cated in these two adjacent clusters. To test this, we ran-
domly selected five additional mIRs located in these two
clusters: miR-127, miR-136, miR-154, miR-337, and
miR-379 to examine their expression in our CLL pa-
tients. Our data indicate that majority of these miRs
were significantly down-regulated (P < 0.001) in most
CLL patients (Fig. 4a). Interestingly, we found that four
out these five mIRs had significantly decreased expres-
sion in chemothrapy-treated CLL patients as compared
to untreated CLL patients (Fig. 4b to f). These findings
are consistent with our miR-377 data, which suggest that
exposure to chemotherapy might trigger transcriptional
silencing of the miRs located in the 14q32 region. Simi-
lar differences in the expression of these mIRs were seen
in the ABT-199R cell lines compared to parental S6 and
OC cells (Fig. 4g).
Previously treated CLL patients show higher BCL-xL
expression
The current standard of care for CLL patients involves
sequential cycles of chemotherapy - most often purine
analogs or alkylating agents - in combination with an
anti-CD20 monoclonal antibody. As almost all CLL pa-
tients will eventually relapse, development of acquired
resistance to chemotherapy is a significant clinical prob-
lem. As 31 of our 76 patients had received a diverse
array of chemotherapy regimens, including fludarabine,
rituximab, bendamustine, chlorambucil, prednisone, and
alemtuzumab, we compared the expression of anti-
apoptotic BCL-2 family genes in untreated compared to
previously treated patients (Fig. 5). Among all the anti-
apoptotic BCL-2 family genes tested, only BCL-xL
expression was significantly higher (P = 0.007) in CLL
patients who received chemotherapy as compared to
those who were never treated (Fig. 5a). This result
indicates that regardless of the type of therapy used,
BCL-xL might confer resistance to conventional cyto-
toxic chemotherapy.
High BCL-xL expression is associated with shorter
treatment-free survival in CLL patients
Baseline characteristics of the 76 patients with CLL stud-
ied are summarized in Table 2. To further investigate
whether expression of anti-apoptotic genes, including
BCL-xL, contribute to treatment free survival in CLL pa-
tients, RT-PCR was used to assess expression of the anti-
apoptotic, BCL-2, MCL-1, BCL-xL, BFL-1, BCL-W, and
BCL-B and pro-apoptotic, BIM, PUMA, and NOXA genes.
Correlations of the expression of each of these genes with
time from diagnosis to start of treatment, i.e., treatment-
free survival (Fig. 6, Additional file 3: Figure S3) were ex-
amined for significance. We also examined the combined
expression of all anti-apoptotic and pro-apoptotic BCL-2
family members and ratios of these (data not shown).
Only BCL-xL expression emerged as being significantly
correlated with treatment-free survival (P = 0.002, Fig. 6a).
We next assessed the correlation of common CLL prog-
nostic markers p53, ZAP70, and CD38 with treatment-
free survival. Patients with p53 (17p) deletion showed very
strong correlation with treatment-free survival, whereas
ZAP70 and CD38 failed to indicate such correlation
(Fig. 7a, c, and e). In contrast, Jonckheere-Terpstra
testing showed no significant correlation trend between
BCL-xL expression and increasing Rai stage, ZAP70-
positive/negative, CD38-positive/negative, p53 deletion
(17p)/normal status (Additional file 4: Figure S4), or
commonly detected chromosomal abnormalities (Table 2),
thus indicating that BCL-xL expression is independent of
known CLL prognostic markers.
BCL-xL expression identifies CLL patients at high risk for
shorter treatment-free survival time within the negative-
prognostic marker groups
Some patients in the ZAP70-negative, CD38-negative,
and normal/unknown p53 (17p) status categories also
experienced rapid progression and aggressive disease
(Fig. 7a, c, and e). BCL-xL expression was able to identify
(See figure on previous page.)
Fig. 2 BCL-xL and miR-377 co-regulation mediates ABT-199 resistance. RT-PCR analysis of BCL-xL, miR-377, and BCL-2 expression levels after
treatment with 5-Aza for 72 h in (a) OC-R and (b) S6-R cells. BCL-xL, miR-377, and BCL-2 expression levels in OC-R and S6-R were normalized to
those in parental OC and S6 cells. DMSO treatment and BCL-2 expression served as negative controls. (c) Parental OC, S6 and ABT-199R OC-R and
S6-R cells were treated with 5-Aza and cell viability was assessed after 72 h by annexin-V/FITC and propidium iodide staining and analyzed by
flow cytometry. (d) Cell viability, analyzed by flow cytometry and (e) BCL-xL expression, assessed by immunoblot after transfecting S6-R cells with
200 nM of Non-Target (N.T), miR-377 mimic, or siBCL-xL. S6-R cells were transfected with 1 μg of pMIG-Bcl-xL expression plasmid and 24 h later
transfected again with 200 nM of miR-377 mimic. After an additional 24 h, analysis of BCL-xL expression by RT-PCR (f) and cell viability (g) were
determined. BCL-xL expression and cell viability were normalized to untransfected S6-R cells. Cell viability (h) and BCL-xL expression (i) were
assessed in S6-R cells treated with 5-Aza for 24 h and then at 48 h following transfection with miR-377 inhibitor (72 h total time). Significance was
determined by a t-test
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patients with high risk within these favorable CLL cat-
egories. Remarkably, BCL-xL levels could discriminate
between patients at high risk who had CD38-negative
(P = 0.010), ZAP70-negative (P = 0.019), or normal/un-
known p53 (17p) status (P = 0.047), suggesting its po-
tential clinical value (Fig. 7b, d, and f ).
Discussion
CLL undergoes transformation (known as the Richter
syndrome), to more aggressive lymphoma, most com-
monly DLBCL [38]. In our GCB-DLBCL chemothera-
peutic resistance model, chronic exposure to ABT-199
up-regulates BCL-xL expression, which is responsible
for mediating chemotherapeutic resistance to ABT-199
[31]. In search of the molecular mechanism that medi-
ates high BCL-xL expression, we identified miR-377, ex-
pression of which was inversely correlated with that of
BCL-xL. In our ABT-199 resistance model, we found
that the high BCL-xL expression was due to down-
regulation of miR-377, an observation similar to what
we found in our CLL patients and a panel of lymphoid
B-cell lines. We demonstrate that BCL-xL is a direct
target of miR-377 by three independent approaches: (i) a
luciferase reporter assay, (ii) miR-377 expression modu-
lation both by a mimic and an inhibitor and (iii) over
expression of BCL-xL. While little is known about the
molecular function of miR-377, in a comprehensive
study using integrative genomic approaches, miR-377,
among other miRNAs, was found to correlate with
advanced tumor stage in solid tumors [39, 40]. Here, we
provide evidence for a tight regulation between miR-377
expression and up-regulation of BCL-xL. Based on these
data, we propose a novel mechanism by which lymphoid
malignant cells regulate BCL-xL and miR-377 expression
in order to promote acquired resistance to chemother-
apy. Interestingly, BCL-xL is one of the most frequently
amplified oncogenes found in solid tumors [41]. Here
we identify a novel, miR-377-dependent regulation as
an alternative mechanism for BCL-xL expression in
leukemic cells.
miR-377 is located on chromosome 14q, with deletion
of this site indicating its potential role as a tumor sup-
pressor. 14q deletions are also associated with trisomy
12, a hallmark of CLL [42]. As the frequency of the 14q
deletion is relatively low in hematopoietic malignancies,
including CLL [33], it is not likely to provide a common
therapeutic resistance mechanism. Interestingly, there is
a growing interest in the 14q32 chromosomal region
because ~ 53 miRNAs are embedded in two adjacent
clusters (14q32.31 and 14q32.32); those span more
than 200 kb, which were found to be deregulated in
various human diseases, including various cancers,
both hematologic, such as acute promyelocytic leukemia
[43] and of epithelial origin, such as melanoma [44].
These reports support our findings that demethylating
agents can restore expression of these miRNAs, in-
cluding miR-377.
Our ABT-199R model suggests that an alternative,
transcriptional silencing mechanism is responsible for
the low levels of miR-377 that develop after chronic ex-
posure to ABT-199. Our preliminary experiments using
bisulfate genomic sequencing and methylation-specific
PCR could not identify differentially methylated regions.
Future experiments are needed to delineate how methy-
lation regulates expression of miR-377 and other miR-
NAs in the 14q32 cluster. Nevertheless, the epigenetic
modification of miRNA expression by methylation is
well documented. Many miRNAs, including miR-377,
are up-regulated following treatment with 5-Aza, a
hypomethylating agent approved for use in myeloid, but
not lymphoid malignancies [36, 39, 45]. Treatment with
5-Aza led to re-expression of miR-377 leading to de-
creased BCL-xL expression. Interestingly, unlike parental
cells, we found that ABT-199R cells were highly sensitive
to 5-Aza. By modulating miR-377 expression with both
a mimic and an inhibitor, along with re-expression of
BCL-xL, we show that targeting BCL-xL by 5-Aza is a
promising approach to overcome ABT-199 resistance.
As several hypomethylating agents are currently in clin-
ical use [45, 46], this possibility could be quickly tested
in clinical trials.
We show that CLL patients previously treated with a
variety of chemotherapeutic regimens had higher BCL-
xL and lower miR-377 expression as compared to
untreated patients. Moreover, CLL patients with high
BCL-xL/low miR-377 expression also have a more ad-
vanced tumor stage. These clinically relevant data along
with our ABT-199R model suggest that BCL-xL might
be critical for conferring general chemotherapy resist-
ance. In support of our findings, other in vitro studies
(See figure on previous page.)
Fig. 3 miR-377 expression is inversely correlated with that of BCL-xL. a Correlation of BCL-xL and miR-377 expression in a panel of lymphoid B-cell
lines. BCL-xL and miR-377 RNA expression was normalized to that of lymphocytes isolated from healthy donors. b miR-377 expression is inversely
correlated with that of BCL-xL in 43 CLL patients as determined by RT-PCR. Spearman correlation (r) and P values are shown. c CLL patients with high
BCL-xL levels show decreased levels of miR-377 expression as determined by RT-PCR. Each dot represents one CLL patient. d CLL patients with
advanced tumor stage have significantly lower miR-377 and higher BCL-xL expression compared to CLL patients with early tumor stage that
have high miR-377 and lower BCL-xL expression. e miR-377 expression in CLL patients who had received a diverse array of chemotherapy
regimens versus untreated CLL patients
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Fig. 4 (See legend on next page.)
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Fig. 5 High levels of BCL-xL expression in CLL patients previously treated with chemotherapy compared to those untreated. mRNA expression
levels in treated and untreated CLL patients for a BCL-xL, b BCL-2, c MCL-1, d BFL-1, e BCL-W, and f BCL-B, determined by RT-PCR. Significance was
determined by a t-test. RNA expression for each transcript was normalized to that obtained in lymphocytes isolated from healthy donors. Each
dot represents one CLL patient
(See figure on previous page.)
Fig. 4 Five miRNAs in the 14q32.31-32 clusters are coordinately down regulated in CLL patients. a Expression of five miRNAs, as determined by
quantitative RT-PCR in CLL patients. Each dot represents one CLL patient. miRNA expression for each transcript was normalized to that of lymphocytes
isolated from healthy donors as indicated by the strait line (corresponding to value 1). Significance was determined by a t-test. Expression levels of five
miRNAs in treated and untreated CLL patients for b miR-127, c miR-136, d miR-154, e miR-337, and f miR-379. g Expression of five
miRNAs in 14q32.31 and 14q32.32 clusters, as determined by quantitative RT-PCR in ABT-199R cell lines. miRNA expression for each
transcript was normalized to that obtained in lymphocytes isolated from healthy donors, as indicated by the strait line
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also support a role for BCL-xL in promoting chemother-
apy resistance. Thus, chemotherapeutic resistance to a
group of compounds that repress MCL-1 expression has
been linked to high BCL-xL mRNA expression [47]. This
finding indicates that a patient-selection strategy for
development of any MCL-1 inhibitor should focus on
patients with low BCL-xL expression. Moreover, re-
sistance to 122 standard chemotherapy agents corre-
lated with high BCL-xL expression in the NCI 60 cell
line panel [48].
Although the role of BCL-2 and MCL-1 in the mo-
lecular pathogenesis of CLL has been extensively
studied, less is known about the role of the other
anti-apoptotic BCL-2 family members. Here, we have
applied a highly sensitive and quantitative assay to
examine the clinical value of expression for all anti-
apoptotic BCL-2 family genes. Out of all these gene
expression analyses, for individual or different combi-
nations of these genes, only BCL-xL expression had
clinically relevant predictive value. In our patient co-
hort, BCL-2 and MCL-1 levels did not discriminate
between those at risk for short treatment free survival
and those who were not, consistent with previous re-
ports [8, 49].
In contrast to p53 (17p) deletions, ZAP70 and
CD38 did not show significant correlations with treat-
ment free survival in our patient population. Reports
conflict on the significance of ZAP70 and CD38 in
predicting clinical outcome in CLL, likely because of
the lack of a standardized method for determining
what constitutes positive and negative test results
[21, 22, 50]. Interestingly, we found that BCL-xL ex-
pression levels could identify patients at high risk
who were negative for ZAP70 or CD38, suggesting the
possibility that it is a more robust and/or independ-
ent indicator of clinical outcome. While p53 dele-
tions/mutations generally indicate aggressive disease
with poor prognosis, the majority of CLL patients,
which do not have this abnormality, remain heteroge-
neous. BCL-xL expression levels were able to further
stratify this group in terms of time to requiring treat-
ment, indicating that BCL-xL may also be useful in
this context. Our findings that BCL-xL has prognostic
value are not limited to CLL. Similarly, it was re-
ported that high BCL-xL expression correlated with
short overall survival in follicular lymphoma [51]. As
a further support for the role of BCL-xL in a wide
range of B lymphoid malignancies, the clinical out-
come of GCB-DLBCL patients is better than of those
with non-germinal center-DLBCL, likely also due to
the fact that GCB-DLBCL cells have significantly
lower BCL-xL expression [29, 52].
Conclusion
Our study provides new insights into the role of
BCL-xL/miR-377 regulation in chemotherapy resist-
ance in B-cell lymphoid malignancies. As anti-
apoptotic BCL-2 family protein inhibitors have shown
promising results in clinical trials, our findings under-
score the importance of determining expression of
the anti-apoptotic BCL-2 family genes, not only for
choosing the appropriate targeted therapy and chemo-
therapy combination for each patient, but also as a
means of monitoring the expression of these genes
during post-chemotherapy follow-up visits.
Table 2 Baseline characteristics of CLL patients
All Patients BCL-XL <median BCL-XL >median P
(n = 38) (n = 38)
Number Value (range) Number Value (range) No. (%) Value (range)
Age, median (range), years 64 (38–90) 64.5 (38–90) 64 (48–87) N.S.
Sex, male/female 52/24 22/16 30/8 0.08
Rai Stage N = 76
Early (Stage 0/I/II) 59 36 23
Advanced (Stage III/IV) 17 2 15
Zap70 positive 18 of 44 11 of 24 7 of 20 0.937
CD38 positive 22 of 53 10 of 27 12 of 26 0.110
FISH
17p 7 of 35 1 of 19 6 of 16 0.275
11q 6 of 35 4 of 19 2 of 16 0.666
13q14 22 of 35 12 of 18 10 of 17 0.733
Trisomy 12 6 of 35 2 of 17 4 of 16 0.398
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Methods
Cell lines and reagents
Human lymphoid cell lines SU-DHL-6, OCL-LY-19,
Nalm-6, Reh, and IM-9 were obtained from ATCC; Mec-1
and Mec-2 were a gift from Dr Yogen Saunthararajah
(Cleveland Clinic). All cell lines were cultured in RPMI-
1640 medium supplemented with 10 % fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA), and antibiotic-
antimycotic (Gibco, Life Technologies, Gaithersburg, MD).
Cell lines were routinely screened for mycoplasma,
variations in growth rates, changes in morphological
characteristics, and their response to stress with
Annexin V FITC-PI staining; their passage number did
not exceed 20. The development of DLBCL cell lines
with acquired resistance to ABT-199 (ABT-199R) was
previously described [31]. The ABT199-R cells were
Fig. 6 High level of expression of BCL-xL, but not other BCL-2 family members, correlates with treatment-free survival of CLL patients. Kaplan-Meier
curves for correlation of treatment-free survival in CLL patients with expression of: a BCL-xL, b BCL-2, c MCL-1, d BFL-1, e BCL-W, and f BCL-B mRNA levels
were determined by RT-PCR. P values shown are for the log-rank test. RNA expression for each transcript was normalized to that obtained
in lymphocytes isolated from healthy donors
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routinely tested for resistance to ABT-199 and cul-
tured without drug for 72 h before they were used in
experiments.
Luciferase assays
The wild-type (WT)-3’-UTR reporter plasmid was con-
structed by cloning a 384-base pair fragment of the
BCL-xL 3’-UTR spanning the predicted target site for
miR-377 downstream of the firefly luciferase coding
region in the pMIR-REPORT vector (Ambion, Austin,
TX). Site-directed mutagenesis of the putative target
sites for miR-377 in the WT-3’-UTR construct was
carried out to generate the mutant MUT-3’-UTR con-
structs. Nucleotide sequences of the constructs were
confirmed by DNA sequencing. Luciferase assays were
performed as previously described [53]. CHO-K1
Fig. 7 BCL-xL expression identifies CLL patients at high risk for short time to treatment who have negative-prognostic markers. Kaplan-Meier
curves for correlation of treatment-free survival in CLL patients with various prognostic markers: a CD38 positive or negative, b CD38 negative
with high BCL-xL expression, c ZAP70 positive or negative, d ZAP70 negative with high BCL-xL expression, e 17p deletion or 17p normal/unknown
group f 17p normal/unknown group with high BCL-xL expression. Log-rank test P values are shown
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(30,000 cells/well) placed in 24-well plates, 1 day later
were co-transfected using Lipofectamine 2000 (Invitro-
gen), with 100 ng WT-3’-UTR or MUT-3’-UTR firefly
luciferase reporter constructs, 0.5 ng renilla luciferase
reporter plasmid (Promega, Madison, WI) and either
miR-377 or negative control (NC) mimics (10 nM). Cell
lysates were assayed for firefly and renilla luciferase ac-
tivities 48 h after transfection using the dual-luciferase
reporter assay system (Promega) and a Victor3 multilabel
plate reader (PerkinElmer). Renilla luciferase activity
served as a control for transfection efficiency. Data are
shown as the ratio of firefly luciferase activity to renilla
luciferase activity. All experiments were performed at
least three times in triplicate.
Transfections to modulate miR-377 and BCL-xL function
The miR-377 mimic sequence 5’-AUCACACAAAGG
CAACUUUUGU-3’ and a Non-Target (negative control)
were purchased from Qiagen. They were transfected using
HiPerFect transfection reagent (Qiagen, Germantown,
MD) in 293 T cells according to manufacturer’s protocol.
The effect of the miR-377 mimic on BCL-xL levels
was validated at the protein level by western blot using an
antibody against BCL-xL (Santa Cruz Biotechnology).
200 nM of miR-377 mimic (Qiagen), miR-377 inhibitor
(Sigma), pMIG-Bcl-xL expression plasmid [54] (obtained
from Addgene), siBCL-xL, or siControl (Santa Cruz
Biotechnology) transfection in ABT-199R SU-DHL-6
cells was achieved using the Amaxa Nucleofector Kit
V (Lonza, Walkersville, MD, USA) (program number
O-007) according to the manufacturer’s protocol, as
described earlier [31]. siBCL-xL and siControl consist
of pools of 3–5 target-specific 19–25 nt siRNAs.
ABT-199R SU-DHL-6 cells were transfected with 1 μg
of pMIG-Bcl-xL, followed 24 h later by transfection
with 200 nM of miR-377 mimics. After an additional
24 h, BCL-xL expression levels were determined by
quantitative RT-PCR.
Immunoblotting
The cell pellets were lysed with 1 % NP-40 lysis buffer
(20 mmol/L Tris–HCl, pH 7.5; 1 mmol/L EDTA;
150 mmol/L NaCl; 1 % NP-40) phosphatase inhibitors
cocktail 2 and 3 (Sigma) and containing protease inhibi-
tors (Roche) for 30 to 45 min at 4 °C. Protein lysates
were prepared after calculating protein concentration
using the Bradford reagent (Biorad) and 50 μg of protein
was resolved on 10 % SDS-PAGE followed by transfer-
ring to nitrocellulose (Millipore) [30]. Immunoblotting
was performed with primary antibodies against BCL-xL
(Santa Cruz Biotechnology) and β-actin (Sigma). The
secondary anti-mouse antibodies were purchased from
Thermo-Fisher Scientific.
Purification of primary CLL cells and lymphocytes from
healthy donors
Fluorescence in situ hybridization was used as part of
the diagnostic evaluation of CLL patients [11]. Periph-
eral blood samples from 76 patients with CLL and six
healthy donors were obtained with the patients’ in-
formed consent according to protocols approved by the
Cleveland Clinic Institutional Review Board according to
the Declaration of Helsinki. All primary CLL cells were
freshly processed without freezing. Lymphocytes were
purified by Ficoll-Paque PLUS (GE Healthcare) gradient
centrifugation. A lymphocyte sample set isolated from 6
healthy donors was used to establish a baseline compari-
son between mRNA levels in CLL and healthy donors,
with highly purified lymphocytes obtained using the
Gambro Elutra Cell Separation System [11].
Flow cytometry
Cell death was assessed by phosphatidylserine
externalization. Cell lines were stained with fluorescein-
conjugated annexin V (BD Biosciences) and propidium
iodide and analyzed on a BD FACSCalibur flow cytometer.
Raw data were analyzed using the CellQuest Version 5.2.1
software. Results were normalized to survival of untreated
cells. Flow cytometric immunophenotyping using fluores-
cently labeled monoclonal antibodies against ZAP70 and
CD38 was performed at the Cleveland Clinic as part
of diagnostic evaluation on a FACSCanto instrument
(BD Biosciences). Staining protocols were standard lyses/
washing protocols, as previously described [11].
RNA isolation and quantitative RT-PCR
Total RNA was isolated using the Trizol method (Invitro-
gen). 1 μg of RNA samples were reverse transcribed using
the TaqMan reverse transcription kit and amplified using
the SYBR Green Master Mix (Applied Biosystems) and
examined on a 7500 Real-Time PCR system (Applied
Biosystems). Quantitative, real-time reverse transcriptase
polymerase chain reaction (RT-PCR) with the specific
BCL-2 family primers was performed as we have de-
scribed previously [11], using the respective primers for
BCL-2 family and β-actin as a control. For the 5-aza-2’-
deoxycytidine (5-Aza) experiment, RNA was isolated from
ABT-199-resistant (ABT-199R) cell lines SU-DHL-6 and
OCL-LY-19 treated with 5 μM 5-Aza (Sigma) for 72 h and
expression determined by RT-PCR.
miRNA amplification
Megaplex™ RT Primers (Applied Biosystems), which are
380 stem-looped reverse transcripts that enable the syn-
thesis of cDNA for mature miRNAs, were used. The
TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems) was used to make cDNAs for mature miR-
NAs. The SYBR Green Master Mix (Applied Biosystems)
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was used to amplify miR-377, using specific miR-377
primers [55] 5’-GAGCAGAGGTTGCCCTTG-3’ (forward)
and 5’-ACAAAAGTTGCCTTTGTGTGA-3’ (reverse).
The U6 small nuclear RNA primers[55] 5’-CTCGCT
TCGGCAGCACA-3’ (forward) and 5’-AACGCTTCAC
GAATTTGCGT-3’ (reverse) were used as an internal
control.
Statistical analyses
The Cox proportional hazards model was used to identify
significant survival dependencies on covariates. To illustrate
associations, Kaplan-Meier curves were plotted using co-
variates dichotomized at their medians and compared for
significant differences using the log rank test. The
Jonckheere-Terpstra test for trend was used to determine
whether BCL-xL expression was related to increase in Rai
stage. Two sample t-tests were used to compare advance
tumor stages (stages III/IV) vs. early tumor stage
(stages 0/I/II), BCL-xL expression in treated vs. untreated,
ZAP70, CD38, and p53 (17p) status in CLL patients. The
Spearman correlation was used to assess the strength and
direction of association between BCL-xL and miR-377 ex-
pression. All computations were performed in R. P < 0.05
was used to indicate statistical significance. Patient records
were extracted for dates of diagnosis and date of initiation
of CLL-specific therapy in order to calculate time to
progression to disease requiring treatment.
Additional files
Additional file 1: Figure S1. BCL-XL mRNA structure. (A) The 3’-UTR
mRNA of BCL-XL contains two predicted miR-377 binding sites. (B) The
contextual/local secondary structures around the predicted miRNA target
site in the short and full length 3’-UTR of Bcl-xL transcript as predicted by
mFold and Nupack RNA folding algorithms. (JPEG 446 kb)
Additional file 2: Figure S2. Lymphoid B-cell lines with low miR-377/
high BCL-XL expression are more resistant to ABT-199. Cell viability of a
panel of lymphoid B-cell lines after treatment with 200 nM of ABT-199.
(JPEG 105 kb)
Additional file 3: Figure S3. Kaplan-Meier curves for correlation of
treatment-free survival with pro-apoptotic BCL-2 expression levels. (A) PUMA,
(B) NOXA, and (C) BIM. P values shown are for the log-rank test. (JPEG 309 kb)
Additional file 4: Figure S4. Correlation of BCL-XL expression and
CLL prognostic markers. BCL-XL expression, as determined by quantitative
RT-PCR, was plotted against (A) Rai stage, (B) p53 (17p), (C) ZAP70, and
(D) CD38. Significance was determined by a t-test. (JPEG 281 kb)
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